Published on 12 Apr 2024 on Insider Monkey via Yahoo Finance
Here’s Why Exact Sciences Corporation (EXAS) Declined in Q1
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, the fund’s Investor Class fund ARTMX returned 10.41%, Advisor Class fund APDMX posted a return of 10.40%, and Institutional Class fund APHMX returned 10.44%, compared to a 9.50% return for the Russell Midcap Growth Index. Balanced security selection across health care, industrials, consumer staples, consumer discretionary, and communication services led the portfolio to outperform the index in the quarter. In addition, please check the fund’s top five holdings to know its best picks in 2024.
Artisan Mid Cap Fund featured stocks like Exact Sciences Corporation (NASDAQ:EXAS) in the first quarter 2024 investor letter. Headquartered in Madison, Wisconsin, Exact Sciences Corporation (NASDAQ:EXAS) provides cancer screening and diagnostic test products. On April 11, 2024, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $72.95 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 24.64%, and its shares gained 8.85% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market capitalization of $13.243 billion.
Artisan Mid Cap Fund stated the following regarding Exact Sciences Corporation (NASDAQ:EXAS) in its first quarter 2024 investor letter: